Invectys publishes positive clinical results for its IN...
Invectys publishes positive clinical results for its INVAC-1 Phase I Study in Clinical Cancer Research With an extended Phase I and a new delivery method…
Read more
Invectys publishes positive clinical results for its INVAC-1 Phase I Study in Clinical Cancer Research With an extended Phase I and a new delivery method…
Invectys : lutter contre toutes les formes de cancers Avec 382 000 nouveaux cas et 157 400 décès par an, le cancer demeure une priorité absolue en matière de…
8th International Conference on HLA-G July 8th – 9th 2019 Ministère de la Santé et des Solidarités, Paris, France Invectys will be attending the 8th International…
The main product of Invectys is a DNA vaccine targeting Telomerase…
The telomerase enzyme functions as part of a large ensemble of proteins and RNA called the telomerase ribonucleoprotein complex.…
Monoclonal antibodies targeting checkpoint inhibitors are hugely important immunotherapy molecules for the treatment cancers…